Advertisement

Drug Safety

, Volume 24, Issue 9, pp 665–682 | Cite as

Risks and Benefits of Soy Phytoestrogens in Cardiovascular Diseases, Cancer, Climacteric Symptoms and Osteoporosis

  • Cesare R. SirtoriEmail author
Review Article

Abstract

Phytoestrogens, plant chemicals classified as isoflavones, coumestans and lignans, display estrogen-like activity because of their structural similarity to human estrogens and exhibit high affinity binding for the estrogen receptor β. They are common components of food items such as grains, beans, fruits and nuts. Isoflavones are primarily found in soybeans and foods made from soy. In particular, significant therapeutic properties have been generally attributed to soy isoflavones, but most of the claims have been poorly, or not at all, confirmed by well designed clinical trials. Such is the case of the purported role of soy isoflavones in reducing plasma cholesterol levels. This link is now not supported by many authors or by appropriately designed clinical studies. The role of isoflavones in cancer prevention, particularly of tumours under endocrine control (breast, prostate and others) is again only supported by weak to nonexisting clinical evidence. A similar case is that of the prevention/treatment of postmenopausal symptoms and osteoporosis. Disturbing data have been reported on potential negative effects of soy isoflavones on cognitive function in the aged, particularly relating to tofu intake. Recent studies have finally indicated a potential role for soy isoflavones in inducing chromosomal changes in cells exposed in vitro and potentiating chemical carcinogens. These findings may not, however, be extrapolated to clinical conditions. Available data do not appear to unequivocally support beneficial effects of soy isoflavones, and warn against their wide use, in the absence of satisfactory clinical findings.

Keywords

Hormone Replacement Therapy Genistein Isoflavones Daidzein Equol 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

This work was supported in part by The Consiglio Nazionale delle Ricerche of Italy (Progetto: Proprietà Chimico Fisiche dei Medicamenti e loro Sicurezza d’Uso) and by the Ministero dell’Università e della Ricerca Scientifica e Tecnologica, Italy.

References

  1. 1.
    Walz E. Isoflavon- und saponin-glucoside in Soja-Hispida. Justus Liebigs Ann Chem 1931; 489: 118–55Google Scholar
  2. 2.
    Walter ED. Genistein (an isoflavone glucoside) and its aglucone, genistein, from soybeans. J Am Oil Chem Soc 1941; 63: 3273–6Google Scholar
  3. 3.
    Bennetts HW, Underwood EJ, Shier FL. A specific breeding problem of sheep on subterranean clover pastures in Western Australia. Aust J Agric Res 1946; 22: 131–8Google Scholar
  4. 4.
    Axelson M, Sjovall J, Gustafsson B, Setchell KDR. Soya: a dietary source of the non-steroidal oestrogen equol in humans and animals. J Endocrinol 1984; 102: 49–56PubMedGoogle Scholar
  5. 5.
    Setchell KDR, Borriello SP, Hulme P, et al. Non-steroidal oestrogens of dietary origin: possible roles in hormone-dependent disease. Am J Clin Nutr 1984; 40: 569–78PubMedGoogle Scholar
  6. 6.
    Adlercreutz H, Mazur W. Phyto-oestrogens and Western diseases. Ann Med 1997; 95–120Google Scholar
  7. 7.
    van der Schouw YT, de Kleijn MJJ, Peeters PHM, et al. Phytooestrogen and cardiovascular disease risk. Nutr Metab Cardiovasc Dis 2000; 10: 154–67PubMedGoogle Scholar
  8. 8.
    Cassidy A, Bingham S, Setchell KDR. Biological effects of isoflavones present in soy in premenopausal women: implications for the prevention of breast cancer. Am J Clin Nutr 1994; 60: 33–40Google Scholar
  9. 9.
    Tikkanen MJ, Adlercreutz H. Dietary soy-derived isoflavone phytoestrogens. Biochem Pharmacol 2000; 60: 1–5PubMedGoogle Scholar
  10. 10.
    Washburn S, Burke GL, Morgan T, et al. Effect of soy protein supplementation on serum lipoproteins, blood pressure, and menopausal symptoms in perimenopausal women. Menopause 1999; 6: 7–13PubMedGoogle Scholar
  11. 11.
    Blair H, Jordan SE, Peterson T, et al. Variable effects of tyrosine kinase inhibitors on avian osteoclastic activity and reduction of bone loss in ovariectomized rats. J Cell Biochem 1996; 61: 629–37PubMedGoogle Scholar
  12. 12.
    Setchell KDR, Nechemias-Zimmer L, Cai J, et al. Exposure of infants to phytoestrogens from soy infant formulas. Lancet 1997; 350: 23–7PubMedGoogle Scholar
  13. 13.
    Miksicek RJ. Estrogenic flavonoids: structural requirements for biological activity. Proc Soc Exp Biol Med 1995; 208(1): 44–50PubMedGoogle Scholar
  14. 14.
    Joannou GE, Kelly GE, Reeder AY, et al. A urinary profile study of dietary phytoestrogens. The identification and mode of metabolism of new isoflavonoids. J Steroid Biochem Mol Biol 1995; 54: 167–84PubMedGoogle Scholar
  15. 15.
    Xu X, Harris KS, Wang HJ, et al. Bioavailability of soybean isoflavones depends upon gut microflora in women. J Nutr0 1995; 125: 2307–15PubMedGoogle Scholar
  16. 16.
    Karr SC, Lampe JW, Hutchins AM, et al. Urinary isoflavonoid excretion in humans is dose dependent at low to moderate levels of soy-protein consumption. Am J Clin Nutr 1997; 66: 46–51PubMedGoogle Scholar
  17. 17.
    Wang HJ, Murphy PA. Isoflavone content in commercial soybean foods. J Agr Food Chem 1994; 42: 1666–73Google Scholar
  18. 18.
    Adlercreutz H, Honjo H, Higashi A, et al. Urinary excretion of lignans and isoflavonoid phytoestrogens in Japanese men and women consuming a traditional Japanese diet. Am J Clin Nutr 1991; 54: 1093–100PubMedGoogle Scholar
  19. 19.
    Adlercreutz H, Fotsis T, Bannwart C, et al. Determination of urinary lignans and phytoestrogen metabolites, potential antiestrogens and anticarcinogens, in urine of women on various habitual diets. J Steroid Biochem 1986; 25: 791–7PubMedGoogle Scholar
  20. 20.
    Horn Ross PL, Barnes S, Kirk M, et al. Urinary phytoestrogen levels in youngwomen from a multiethnic population. Cancer Epidemiol Biomarkers Prev 1997; 6: 339–45PubMedGoogle Scholar
  21. 21.
    Ignatowski A. Über die Wirkung des tierischen Eiweisses auf die Aorta und die parenchymatösen Organen der Kaninchen. Virchow Arch Pathol Anat Physiol Klin Med 1909; 198: 248–70Google Scholar
  22. 22.
    Sirtori CR, Agradi E, Conti F, et al. Soybean-protein diet in the treatment of type II hyperlipoproteinaemia. Lancet, 1977; I: 275–8Google Scholar
  23. 23.
    Descovich GC, Ceredi C, Gaddi A, et al. Multicenter study of soybean protein diet for outpatient hypercholesterolaemic patients. Lancet 1980; II: 709–12Google Scholar
  24. 24.
    Sirtori CR, Gatti E, Mantero O, et al. Clinical experience with the soybean protein diet in the treatment of hypercholesterolemia. Am J Clin Nutr 1979; 32: 1645–58PubMedGoogle Scholar
  25. 25.
    Hermansen K, Sondergaard M, Hoie L, et al. Beneficial effects of a soy-based dietary supplement on lipid levels and cardiovascular risk markers in type 2 diabetic subjects. Diabetes Care 2001; 24: 228–33PubMedGoogle Scholar
  26. 26.
    Anderson JW, Bryan MJ, Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med 1995; 333: 276–82PubMedGoogle Scholar
  27. 27.
    Sirtori CR, Gianazza E, Manzoni C, et al. Role of isoflavones in the cholesterol reduction by soy proteins in the clinic. Am J Clin Nutr 1997; 65: 166–7PubMedGoogle Scholar
  28. 28.
    Sirtori CR, Galli G, Lovati MR, et al. Effects of dietary proteins in the regulation of liver lipoprotein receptors in rats. J Nutr 1984; 114: 1493–1500PubMedGoogle Scholar
  29. 29.
    Lovati MR, Manzoni C, Corsini A, et al. Low density lipoprotein receptor activity is modulated by soybean globulins in cell culture. J Nutr 1992; 122: 1971–8PubMedGoogle Scholar
  30. 30.
    Lovati MR, Manzoni C, Corsini A. 7S globulin from soybean is metabolised in human cell cultures by a specific uptake and degradation system. J Nutr 1996; 126: 2831–43PubMedGoogle Scholar
  31. 31.
    Lovati MR, Manzoni C, Gianazza E, et al. Soybean protein products as regulators of liver low-density lipoprotein receptors. I. Identification of active β-conglycinin subunits. J Agr Food Chem 1998; 46: 2474–80Google Scholar
  32. 32.
    Lovati MR, Manzoni C, Gianazz E, et al. Soy protein peptides regulate cholesterol homeostasis in Hep G2 cells. J Nutr 2000; 130: 2543–9PubMedGoogle Scholar
  33. 33.
    Lovati MR, Manzoni C, Canavesi A, et al. Soybean protein diet increases low density lipoprotein receptor activity in mononuclear cells from hypercholesterolemic patients. J Clin Invest. 1987; 80: 1498–502PubMedGoogle Scholar
  34. 34.
    Baum JA, Teng H, Erdman JWJ, et al. Long term intake of soy protein improves blood lipid profiles and increases mononuclear cell low-density-lipoprotein receptor messenger RNA in hypercholesterolemic, postmenopausal women. Am J Clin Nutr 1998; 68: 545–51PubMedGoogle Scholar
  35. 35.
    FDA Talk Paper.Washington, D.C.: US Food and Drug Administration Press Office, 1999 Oct 20Google Scholar
  36. 36.
    Anthony MS, Clarkson TB, Hughes Jr CL, et al. Soybean isoflavones improve cardiovascular risk factors without affecting the reproductive system of peripubertal Rhesus monkeys. J Nutr 1996; 126: 43–50PubMedGoogle Scholar
  37. 37.
    Anthony MS, Clarkson TB, Bullock BC, et al. Soy protein versus soy phytoestrogens in the prevention of diet induced coronary artery atherosclerosis of male Cynomolgus monkeys. Arterioscl Thromb Vasc Biol 1997; 17: 2524–31PubMedGoogle Scholar
  38. 38.
    Crouse JR III, Morgan R, Terry JG, et al. A randomised trial comparing the effect of casein with that of soy protein containing varying amounts of isoflavones on plasma concentrations of lipids and lipoproteins. Arch Intern Med 1999; 159: 2070–6PubMedGoogle Scholar
  39. 39.
    Merz-Demlow BE, Duncan AM, Wangen KE, et al. Soy isoflavones improve plasma lipids in normocholesterolemic, premenopausal women. Am J Clin Nutr 2000; 71: 1462–9PubMedGoogle Scholar
  40. 40.
    Greaves KA, Parks JS, Williams JK, et al. Intact dietary soy protein, but not adding an isoflavone-rich soy extract to casein, improves plasma lipids in ovariectomized cynomolgus monkeys. J Nutr 1999; 129: 1585–92PubMedGoogle Scholar
  41. 41.
    Greaves KT, Wilson MD, Rudel LL, et al. Consumption of soy protein reduces cholesterol absorption compared with casein alone or supplemented with an isoflavone extract or conjugated equine estrogen in ovariectomized cynomolgous monkeys. J Nutr 2000; 130: 820–26PubMedGoogle Scholar
  42. 42.
    Nestel PJ, Yamashita T, Sasahara T, et al. Soy isoflavones improve systemic arterial compliance but not plasma lipids in menopausal and perimenopausal women. Arterioscl Thromb Vasc Biol 1997; 17: 3392–8PubMedGoogle Scholar
  43. 43.
    Simons LA, von Konigsmark M, Simons J, et al. Phytoestrogens do not influence lipoprotein levels or endothelial function in healthy, postmenopausal women. Am J Cardiol 2000; 85: 1297–1301PubMedGoogle Scholar
  44. 44.
    Hodgson JM, Puddey IB, Beilin LJ, et al. Supplementation with isoflavonoid phytoestrogens does not alter serum lipid concentrations: a randomised controlled trial in humans. J Nutr 1998; 128: 728–32PubMedGoogle Scholar
  45. 45.
    Samman S, Lyons Wall PM, et al. The effect of supplementation with isoflavones on plasma lipids and oxidisability of low density lipoprotein in premenopausal women. Atherosclerosis 1999; 147: 277–83PubMedGoogle Scholar
  46. 46.
    Nestel PJ, Pomeroy S, Kay S, et al. Isoflavones from red clover improve systemic arterial compliance but not plasma lipids in menopausal women. J Clin Endocrinol Metab 1999; 84: 895–8PubMedGoogle Scholar
  47. 47.
    Howes JB, Sullivan D, Lai N. The effects of dietary supplementation with isoflavones from red clover on the lipoprotein profile of post menopausal women with mild to moderate hypercholesterolemia. Atherosclerosis 2000; 152: 143–7PubMedGoogle Scholar
  48. 48.
    Erdman JW. Soy protein and cardiovascular disease: a statement for healthcare professionals from the Nutrition Committee of the AHA. Circulation 2000; 102: 2555–9PubMedGoogle Scholar
  49. 49.
    Peluso MR, Winters TA, Shanahan MF, et al. A cooperative interaction between soy protein and its isoflavones-enriched fraction lowers hepatic lipids inmale obese Zucker rats and reduces blood platelet sensitivity in male Sprague-Dawley rats. J Nutr 2000; 130: 2333–42PubMedGoogle Scholar
  50. 50.
    Sfakianos J, Coward L, Kirk M. Intestinal uptake and biliary excretion of the isoflavone genistein in rats. J Nutrition 1997; 127: 1260–8Google Scholar
  51. 51.
    Kirk EA, Sutherland P, Wang SA, et al. Dietary isoflavones reduce plasma cholesterol and atherosclerosis in C57BL/6 mice but not LDL receptor-deficient mice. J Nutr 1998; 128: 954–9PubMedGoogle Scholar
  52. 52.
    Jager W, Winter O, Halper B, et al. Modulation of liver canalicular transport processes by the tyrosine-kinase inhibitor genistein: implications of genistein metabolism in the rat. Hepatology 1997; 26: 1467–76PubMedGoogle Scholar
  53. 53.
    Jager W, Sartor M, Herzo W, et al. Genistein metabolism in liver microsomes of Wistar and mutant TR(-)-rats. Res Comm Mol Pathol Pharmacol 1998; 100: 105–16Google Scholar
  54. 54.
    Lamon-Fava S. Genistein activates apolipoproteins A-I gene expression in the human hepatoma cell line HepG2. J Nutr 2000; 130: 2489–92PubMedGoogle Scholar
  55. 55.
    Kurzer MS, Xu X. Dietary phytoestrogens. Annu Rev Nutr 1997; 353–81Google Scholar
  56. 56.
    Tikkanen MJ, Wahala K, Ojala S, et al. Effect of soybean phytoestrogen intake on low density lipoprotein oxidation resistance. Proc Natl Acad Sci U S A 1998; 95: 3106–10PubMedGoogle Scholar
  57. 57.
    Wagner JD, Cefalu WT, Anthony MS, et al. Dietary soy protein and estrogen replacement therapy improve cardiovascular risk factors and decrease aortic cholesteryl ester content in ovariectomized cynomolgus monkeys. Metabolism 1997; 46: 698–705PubMedGoogle Scholar
  58. 58.
    Kapiotis S, Hermann M, Held I, et al. Genistein, the dietary-derived angiogenesis inhibitor, prevents LDL oxidation and protects endothelial cells from damage by atherogenic LDL. Arterioscler Thromb Vasc Biol 1997; 17: 2868–74PubMedGoogle Scholar
  59. 59.
    Kerry N, Abbey M. The isoflavone genistein inhibits copper and peroxyl radical mediated low density lipoprotein oxidation in vitro. Atherosclererosis 1998; 140: 341–7Google Scholar
  60. 60.
    Wiseman H, O’Reilly JD, Adlercreutz H, et al. Isoflavone phytoestrogens consumed in soy decrease F2-isoprostane concentrations and increase resistance of low-density lipoprotein to oxidation in humans. Am J Clin Nutr 2000; 72: 395–400PubMedGoogle Scholar
  61. 61.
    Jenkins DJ, Kendall CW, Vidgen E, et al. Health aspects of partially defatted flaxseed, including effects on serum lipids, oxidative measures, and ex vivo androgen and progestin activity: a controlled crossover trial. Am J Clin Nutr 1999; 69: 395–402PubMedGoogle Scholar
  62. 62.
    Hodgson JM, Puddey IB, Croft KD, et al. Isoflavonoids do not inhibit in vivo lipid peroxidation in subjects with high-normal blood pressure. Atherosclerosis 1999; 145: 167–72PubMedGoogle Scholar
  63. 63.
    Honoré EK, Williams JK, Anthony MS, et al. Soy isoflavones enhance vascular reactivity in atherosclerotic female macaques. Fertil Steril 1997; 67: 148–54PubMedGoogle Scholar
  64. 64.
    Anthony MS. Soy and cardiovascular disease: cholesterol lowering and beyond. J Nutr 2000: 130: 662S–3SPubMedGoogle Scholar
  65. 65.
    Walker HA, Dean TS, Sanders TAB, et al. The phytoestrogen genistein produces acute nitric oxide-dependent dilation of human forearm vasculature with similar potency to 17β-estradiol. Circulation 2001; 103: 258–62PubMedGoogle Scholar
  66. 66.
    Adlercreutz H, Markkanen H, Watanabe S. Plasma concentrations of phyto-oestrogens in Japanese men. Lancet 1993; 342: 1209–10PubMedGoogle Scholar
  67. 67.
    Williams JK, Clarkson TB. Dietary soy isoflavones inhibit in vivo constrictor responses of coronary arteries to collagen induced platelet activation. Coron Artery Dis 1998; 9: 759–64PubMedGoogle Scholar
  68. 68.
    Schoene NW, Guidry CA. Dietary soy isoflavones inhibit activation of rat platelets. J Nutr Biochem 1999; 10: 421–6PubMedGoogle Scholar
  69. 69.
    Kuiper GG, Lemmen JG, Carlsson B, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology 1998; 139: 4252–63PubMedGoogle Scholar
  70. 70.
    Mäkelä S, Savolainen H, Aavik E et al. Differentiation between vasculoprotective and uterotrophic effects of ligands with different binding affinities to estrogen receptors aand β. Proc Natl Acad Sci U S A 1999; 96: 7077–82PubMedGoogle Scholar
  71. 71.
    Shimokado K, Yokota T, Umezawa K, et al. Protein tyrosine kinase inhibitors inhibit chemotaxis of vascular smooth muscle cells. Arterioscler Thromb 1994; 14: 973–81PubMedGoogle Scholar
  72. 72.
    Shimokado K, Umezawa K, Ogata J. Tyrosine kinase inhibitors inhibit multiple steps of the cell cycle of vascular smooth muscle cells. Exp Cell Res 1995; 220: 266–73PubMedGoogle Scholar
  73. 73.
    Wagner JD, Zhang L, Greaves KA, et al. Soy protein reduces the arterial low-density lipoprotein (LDL) concentration and delivery of LDL cholesterol to the arteries of diabetic and nondiabetic male cynomolgus monkeys. Metabolism 2000; 49: 1188–96PubMedGoogle Scholar
  74. 74.
    Parkin DM. Cancers of the breast, endometrium and ovary: geographic correlations. Eur J Cancer Clin Oncol 1989; 25: 1917–25PubMedGoogle Scholar
  75. 75.
    Rose DP, Boyar AP, Wynder EL. International comparison of mortality rates for cancer of the breast, ovary, prostate and colon, and per capita food consumption. Cancer 1986; 58: 2363–71PubMedGoogle Scholar
  76. 76.
    Gao YH, Yamaguchi M. Inhibitory effect of genistein on osteoclast-like cell formation in mouse marrow cultures. Biochem Pharmacol 1999; 58: 767–72PubMedGoogle Scholar
  77. 77.
    Fanti P, Monier-Faugere MC, Geng Z, et al. The phytoestrogen genistein reduces bone loss in short term ovariectomized rats. Osteoporosis Int 1998; 8: 274–81Google Scholar
  78. 78.
    Kuiper GG, Enmark E, Pelto-Huikko M, et al. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996; 93: 5925–30PubMedGoogle Scholar
  79. 79.
    Kuiper GG, Carlsson B, Grandien K, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997; 138: 863–70PubMedGoogle Scholar
  80. 80.
    Akiyama T, Ishida J, Nakagawa S, et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 1987; 262: 5592–95PubMedGoogle Scholar
  81. 81.
    Sathyamoorthy N, Gilsdorf JS, Wang TT. Differential effect of genistein on transforming growth factor beta 1 expression in normal and malignant mammary epithelial cells. Anticancer Res 1998; 18: 2449–53PubMedGoogle Scholar
  82. 82.
    Kim H, Peterson TG, Barnes S. Mechanisms of action of the soy isoflavone genistein: emerging role of its effects through transforming growth factor beta signaling pathways. Am J Clin Nutr 1998; 68: 1418S–25SPubMedGoogle Scholar
  83. 83.
    Li D, Yee JA, McGuire MH, et al. Soybean isoflavones reduce experimental metastasis in mice. J Nutr 1999; 129: 1075–78PubMedGoogle Scholar
  84. 84.
    Li Y, Bhuiyan M, Sarkar FH. Induction of apoptosis and inhibition of c-erbB-2 in MDA-MB-435 cells by genistein. Int J Oncol 1999; 15: 525–33PubMedGoogle Scholar
  85. 85.
    Schleicher RL, Lamartiniere CA, Zheng M, et al. The inhibitory effect of genistein on the growth and metastasis of a transplantable rat accessory sex gland carcinoma. Cancer Lett 1999; 136: 195–201PubMedGoogle Scholar
  86. 86.
    Fotsis T, Pepper M, Adlercreutz H, et al. Genistein, a dietaryderived inhibitor of in vitro angiogenesis. Proc Natl Acad Sci U S A 1993; 90: 2690–4PubMedGoogle Scholar
  87. 87.
    Zhou JR, Gugger ET, Tanaka T, et al. Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumour angiogenesis in mice. J Nutr 1999; 129: 1628–35PubMedGoogle Scholar
  88. 88.
    Peterson TG, Coward L, Kirk M, et al. Isoflavones and breast epithelial cell growth: the importance of genistein and biochanin A metabolism in the breast. Carcinogenesis 1996; 17: 1861–9PubMedGoogle Scholar
  89. 89.
    Peterson TG, Ji G-P, Kirk M, et al. Metabolism of the isoflavones genistein and biochanin A in human breast cancer cell lines. Am J Clin Nutr 1998; 68: 1505S–11SPubMedGoogle Scholar
  90. 90.
    Boersma BJ, Patel RP, Kir M, et al. Chlorination and nitration of soy isoflavones. Arch Bio chem Biophys 1999; 368: 265–75Google Scholar
  91. 91.
    Brown M. Estrogen receptor molecular biology. Hematol Oncol Clin North Am 1994; 8: 101–12PubMedGoogle Scholar
  92. 92.
    Barnes S, Kim H, Darley-Usmar V, et al. Beyond ERα and ERβ: estrogen receptor binding is only part of the isoflavone story. J Nutr 2000; 130: 656S–7SPubMedGoogle Scholar
  93. 93.
    Lee HP, Gourley L, Duggu SW, et al. Dietary effects on breast cancer risk in Singapore. Lancet 1991; 337: 1197–1200PubMedGoogle Scholar
  94. 94.
    Yuan JM, Wang QS, Ross RK, et al. Diet and breast cancer in Shanghai and Tianjin, China Br J Cancer 1995; 71: 1353–8Google Scholar
  95. 95.
    Zheng W, Dai Q, Custer LJ, et al. Urinary excretion of isoflavonoids and the risk of breast cancer. Cancer Epidemiol Biomarkers Prev 1999; 8: 35–40PubMedGoogle Scholar
  96. 96.
    McMichael Phillips DF, Harding C, Morton M, et al. Effects of soy-protein supplementation on epithelial proliferation in the histologically normal human breast. Am J Clin Nutr 1998; 68: 1431S–5SPubMedGoogle Scholar
  97. 97.
    Hargreaves DF, Potten CS, Harding C, et al. Two-week dietary soy supplementation has an estrogenic effect on normal premenopausal breast. J Clin Endocrinol Metab 1999; 84: 4017–24PubMedGoogle Scholar
  98. 98.
    Ingram D, Sanders K, Kolybaba M, et al. Case-control study of phyto-oestrogens and breast cancer. Lancet 1997; 350: 990–4PubMedGoogle Scholar
  99. 99.
    Finkel E. Phyto-oestrogens: the way to postmenopausal health? [editorial]. Lancet 1998; 352: 1762PubMedGoogle Scholar
  100. 100.
    Goodman MT, Wilkens LR, Hankin JH, et al. Association of soy and fibre consumption with the risk of endometrial cancer. Am J Epidemiol 1997; 146: 294–306PubMedGoogle Scholar
  101. 101.
    Cline JM, Paschold JC, Anthony MS, et al. Effects of hormonal therapies and dietary soy phytoestrogens on vaginal cytology in surgically postmenopausal macaques. Fertil Steril 1996; 65: 1031–5PubMedGoogle Scholar
  102. 102.
    Tansey G, Hughes Jr CL, Cline JM, et al. Effects of dietary soybean estrogens on the reproductive tract in female rats. Proc Soc Exp Biol Med 1998; 217: 340–4PubMedGoogle Scholar
  103. 103.
    Foth D, Cline JM. Effects of mammalian and plant estrogens on mammary glands and uteri of macaques. Am J Clin Nutr 1998; 68: 1413S–7SPubMedGoogle Scholar
  104. 104.
    Cohen LA, Zhao Z, Pittman B, et al. Effect of intact and isoflavone-depleted soy protein on NMU-induced rat mammary tumourigenesis. Carginogenesis 2000; 21: 929–35Google Scholar
  105. 105.
    Petrakis NL, Barnes S, King EB, et al. Stimulatory influence of soy protein isolate on breast secretion in pre- and postmenopausal women. Cancer Epidemiol Biomark Prev 1996; 5: 785–94Google Scholar
  106. 106.
    Lu L-JW, Anderson KE, Grady JJ, et al. Effects of soya consumption for one month on steroid hormones in premenopausal women: implications for breast cancer risk reduction. Cancer Epidemiol Biomark Prev 1996; 5: 63–70Google Scholar
  107. 107.
    Nagata C, Takatsuka N, Inaba S, et al. Effect of soymilk consumption on serum estrogen concentrations in premenopausal Japanese women. J Natl Cancer Inst 1998; 90: 1830–5PubMedGoogle Scholar
  108. 108.
    Duncan AM, Merz BE, Xu X, et al. Soy isoflavones exert modest effects in premenopausal women. J Clin Endocrinol Metab 1999; 84: 192–7PubMedGoogle Scholar
  109. 109.
    Cassidy A, Bingham S, Setchell K. Biological effects of isoflavones in young women: importance of the chemical composition of soyabean products. Br J Nutr 1995; 74: 587–601PubMedGoogle Scholar
  110. 110.
    Messina JM. Legumes and soybeans: Overview of their nutritional profiles and health effects. Am J Clin Nutr 1999; 70: 439S–50SPubMedGoogle Scholar
  111. 111.
    Bouker KB, HilakiviClarke L. Genistein: does it prevent or promote breast cancer? Envinron Health Perspect 2000; 108: 701–9Google Scholar
  112. 112.
    Oishi K, Okada K, Yoshida O, et al. A case-control study of prostatic cancer with reference to dietary habits. Prostate 1988; 12: 179–90PubMedGoogle Scholar
  113. 113.
    Mills PK, Beeson WL, Phillips RL, et al. Cohort study of diet, lifestyle and prostate cancer in Adventist men. Cancer 1989; 64: 598–604PubMedGoogle Scholar
  114. 114.
    Severson RK, Nomura AMY, Grove S, et al. A prospective study of demographics and prostate cancer among men of Japanese ancestry in Hawaii. Cancer Res 1989; 49: 1857–60PubMedGoogle Scholar
  115. 115.
    Adlercreutz CHT, Goldin BR, Gorbach SL, et al. Soybean phytoestrogen intake and cancer risk. J Nutr 1995; 125: 757S–70SPubMedGoogle Scholar
  116. 116.
    Kondo K, Tsuneizumi K, Watanabe T, et al. Induction of in vitro differentiation of mouse embryonal carcinoma (F9) cells by inhibitors of topoisomerases. Cancer Res 1991; 51: 5398–404PubMedGoogle Scholar
  117. 117.
    Adlercreutz H. Phytoestrogens: epidemiology and a possible role in cancer protection. Environ Health Perspect 1995; 103: 103–12PubMedGoogle Scholar
  118. 118.
    Urban D, Irwin W, Kirk M, et al. The effect of isolated soy protein on-plasma biomarkers in elderly men with elevated serum prostate specific antigen. J Urol 2001; 165: 294–300PubMedGoogle Scholar
  119. 119.
    Stephens FO. Phytoestrogens and prostate cancer: possible preventive role. Med J Aust 1997; 167: 138PubMedGoogle Scholar
  120. 120.
    Peterson G, Barnes S. Genistein and biochanin-A inhibit the growth of human prostate cancer cells but not epidermal growth factor receptor tyrosine autophosphorylation. Prostate 1993; 22: 335–45PubMedGoogle Scholar
  121. 121.
    Adlercreutz H, Mazur W, Bartels P, et al. Phyto-oestrogen and prostate disease. J Nutr 2000; 130: 658S–9SPubMedGoogle Scholar
  122. 122.
    Mäkelä SI, Pylkkänen LH, Santti RS, Adlercreutz H. Dietary soybean may be antiestrogenic in male mice. J Nutr 1995; 125: 437–45PubMedGoogle Scholar
  123. 123.
    Evans BAJ, Griffiths K, Morton MS. Inhibition of 5-α reductase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavonoids. J Endocrinol 1995; 147: 295–302PubMedGoogle Scholar
  124. 124.
    Potter SM, Baum JA, Teng HY, et al. Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women. Am J Clin Nutr 1998; 1375S–9SGoogle Scholar
  125. 125.
    Wangen KE, Duncan AM, Merz-Demlow BE, et al. Effects of soy isoflavones on markers of bone turnover in premenopausal and postmenopausal women. J Clin Endocrinol Metab 2000; 85: 3043–8PubMedGoogle Scholar
  126. 126.
    Arjmandi BH, Birbaum R, Goyal NV, et al. Bone sparing effect of soy protein in ovarian hormone-deficient rats is related to its isoflavone content. Am J Clin Nutr 1998; 68: 1364S–68SPubMedGoogle Scholar
  127. 127.
    Jayo MJ, Anthony MS, Registe TC et al. Dietary soy isoflavones and bone loss in ovariectomized monkeys [abstract]. FASEB J 1997; 11: S228Google Scholar
  128. 128.
    Somekawa Y, Chiguchi M, Ishibashi T, et al. Soy intake related to menopausal symptoms, serum lipids, and bone mineral density in postmenopausal Japanese women. Obstet Gynecol 2001; 97: 109–15PubMedGoogle Scholar
  129. 129.
    Kardinaal AF, Morton MS, Bruggemann Rotgans IE, et al. Phyto-oestrogen excretion and rate of bone loss in postmenopausal women. Eur J Clin Nutr 1998; 52: 850–5PubMedGoogle Scholar
  130. 130.
    Burke GL, Vitolins MZ, Bland D. Soybean isoflavones as an alternative to traditional hormone replacement therapy: are we there yet? J Nutr 2000; 130: 664S–5SPubMedGoogle Scholar
  131. 131.
    Manolio TA, Furberg CD, Shemanski L, et al. Associations of postmenopausal estrogen use with cardiovascular disease and its risk factors in older women. The CHS Collaborative Research Group. Circulation 1993; 88: 2163–71Google Scholar
  132. 132.
    Nabulsi AA, Folsom AR, White A, et al. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators. N Engl J Med 1993; 328: 1069–75PubMedGoogle Scholar
  133. 133.
    Brzezinski A, Adlercreutz H, Shaoul R, et al. Short term effects of phytoestrogens-rich diet on postmenopausal women. Menopause 1997; 4: 89–94Google Scholar
  134. 134.
    Duncan AM, Underhill KEW, X X, et al. Modest hormonal effects of soy isoflavones in postmenopausal women. J Clin Endocrinol Metab 1999: 84: 3479–84PubMedGoogle Scholar
  135. 135.
    Kurzer MS. Hormonal effects of soy isoflavones: studies in premenopausal and postmenopausal women. J Nutr 2000; 130: 660S–1SPubMedGoogle Scholar
  136. 136.
    Murkies AL, Lombard C, Strauss BJG, et al. Dietary flour supplementation decreases post-menopausal hot flushes: effect of soy and wheat. Maturitas 1995; 21: 189–95PubMedGoogle Scholar
  137. 137.
    Albertazzi P, Pansini F, Bonaccorsi G, et al. The effect of dietary soy supplementation on hot flushes. Obstet Gynecol 1998; 91: 6–11PubMedGoogle Scholar
  138. 138.
    Quella SK, Loprinzi CL, Barton DL, et al. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group Trial. J Clin Oncol 2000; 18: 1068–74PubMedGoogle Scholar
  139. 139.
    Baird DD, Umbach DM, Lansdell L, et al. Dietary intervention study to assess estrogenicity of dietary soy among post-menopausal women. J Clin Endocrinol Metab 1995; 80: 1685–90PubMedGoogle Scholar
  140. 140.
    Cline JM, Hughes Jr CL, Phytochemicals for the prevention of breast and endometrial cancer. Cancer Treat Res 1998; 94: 107–34PubMedGoogle Scholar
  141. 141.
    Vincent A, Fitzpatrick LA. Soy isoflavones: are they useful in menopause? Mayo Clinic Proceedings 2000; 75: 1174–84PubMedGoogle Scholar
  142. 142.
    Anonymous. The role of isoflavones in menopausal health-Consensus opinion of The North American Menopause Society. Menopause 2000; 7: 215—29Google Scholar
  143. 143.
    Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 1998; 19: 55–72PubMedGoogle Scholar
  144. 144.
    Yaffe K, Grady D, Pressman A, et al. Serum estrogen levels, cognitive performance, and risk of cognitive decline in older community women. J Am Geriatr Soc 1998; 46: 816–21PubMedGoogle Scholar
  145. 145.
    Yaffe K, Sawaya G, Grady D. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA 1998; 279: 688–95PubMedGoogle Scholar
  146. 146.
    White L, Petrovitch H, Ross GW, et al. Association of mid-life consumption of tofu with late life cognitive impairment and dementia: the Honolulu-Asia Aging Study [abstract]. Neurobiol Aging 1996 17: 5121Google Scholar
  147. 147.
    Pan Y, Anthony M, Clarkson TB. Effect of estradiol and soy phytoestrogens on choline acetyltransferase and nerve growth factor mRNAs in the frontal cortex and hippocampus of female rats. Proc Soc Exp Biol Med 1999; 221: 118–25PubMedGoogle Scholar
  148. 148.
    Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomised controlled trial. Alzheimer’s Disease Cooperative Study. JAMA 2000; 283: 1007–15PubMedGoogle Scholar
  149. 149.
    White LR, Petrovitch H, Ross GW, et al. Brain aging and midlife tofu consumption. J Am Coll Nutr 2000; 19: 242–558PubMedGoogle Scholar
  150. 150.
    Kulling SE, Metzler M. Induction of micronuclei, DNA strand breaks and HPRT mutations in cultured Chinese hamster V79 cells by the phytoestrogen coumoestrol. Food Chem Toxicol 1997; 35: 605–13PubMedGoogle Scholar
  151. 151.
    Kulling SE, Rosenberg B, Jacobs E, et al. The phytoestrogen coumoestrol and genistein induce structural chromosomal aberrations in cultured human peripheral blood lymphocytes. Arch Toxicol 1999; 73: 50–4PubMedGoogle Scholar
  152. 152.
    Kaufmann WK. Human topoisomerase II function, tyrosine phosphorylation and cell cycle checkpoints. Proc Soc Exp Biol Med 1998; 217: 327–34PubMedGoogle Scholar
  153. 153.
    Reinhart KC, Dubey RK, Keller PJ, et al. Xeno-oestrogens and phyto-oestrogens induce the synthesis of leukaemia inhibitory factor by human and bovine oviduct cells. Mol Hum Reprod 1999; 10: 899–907Google Scholar
  154. 154.
    Abe T. Infantile leukaemia and soybeans: a hypothesis. Leukaemia 1999; 13: 317–20Google Scholar
  155. 155.
    Plewa MJ, Wagner ED, Berhow MA, et al. Antimutagenic activity of chemical fractions isolated from a commercial soybean processin by-product. Teratogenesis, Carcinogenesis, and Mutagenesis 1999; 19: 121–35PubMedGoogle Scholar
  156. 156.
    McCabe Jr MJ, Orrenius S. Genistein induces apoptosis in immature human thymocytes by inhibiting topoisomerase II. Biochem Biophys Res Commun 1993. 194: 944–50PubMedGoogle Scholar
  157. 157.
    Traganos F, Ardelt B, Halko N, et al. Effects of genistein of the growth and cell cycle progression of normal human lymphocytes and human leukaemicMOLT-4 andHL-60 cells. Cancer Res 1992; 6200–8Google Scholar
  158. 158.
    Kumi-Diaka J, Rodrigue R, Doudazi G. Influence of genistein (4′,5,7-thrihydroxyisoflavone) on the growth and proliferation of testicular cell lines. Biol Cell 1998; 90: 349–54PubMedGoogle Scholar
  159. 159.
    Kumi-Diaka J, Ngguyen V, Butler A. Cytotoxic potential of the phytochemical genistein isoflavone (4′,5′,7-trihydroxyisoflavone) and certain environmental chemical compounds on testicular cells. Biol Cell 1999; 91: 515–23PubMedGoogle Scholar
  160. 160.
    Fort P, Moses N, Fasano M, et al. Breast and soy-formula feedings in early infancy and the prevalence of autoimmune thyroid disease in children. J Am Coll Nutr 1990: 9: 164–7PubMedGoogle Scholar
  161. 161.
    Divi RL, Chang HC, Doerge DR. Anti-thyroid isoflavones from soybean. Biochem Pharmacol 1997; 54: 1087–96PubMedGoogle Scholar
  162. 162.
    Stocker R. Dietary and pharmacological antioxidants in atherosclerosis. Curr Opin Lipidol 1999; 10: 589–97PubMedGoogle Scholar
  163. 163.
    Blakely JA. The Heart and Estrogen/Progestin Replacement Study revisited: hormone replacement therapy produced net harm, consistent with the observational data. Arch Intern Med 2000; 160: 2897–900PubMedGoogle Scholar
  164. 164.
    Ginsburg J, Prelevic GM. Lack of significant hormonal effects and controlled trials of phyto-oestrogen. Lancet 2000; 355: 163–4PubMedGoogle Scholar
  165. 165.
    Sirtori CR. Dubious benefits and potential risk of soy phytooestrogens. Lancet 2000; 355: 849PubMedGoogle Scholar
  166. 166.
    Impiego di Citrus aurantium, Hypericum perforatum e di Isoflavoni nel settore alimentare. Circular Letter. Rome: Ministero della Sanità, 1999 Oct 20 (600.12/AG45.1/2688)Google Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  1. 1.Institute of Pharmacological SciencesUniversity of MilanoMilanoItaly

Personalised recommendations